Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats.

Amer Talbi,Di Zhao,Qingwang Liu,Junxiu Li,Ali Fan,Wei Yang,Xing Han,Xijing Chen

DOI: https://doi.org/10.3390/molecules19055538

IF: 4.6

2014-01-01

Molecules

Abstract:Wogonin is a natural anticancer candidate. The purpose of this study was to explore the pharmacokinetic profiles, tissue distribution, excretion and plasma protein binding of wogonin in Sprague-Dawley rats. A rapid, sensitive, and specific LC-MS/MS method has been developed for the determination of wogonin in different rat biological samples. After i.v. dosing of wogonin at different levels (10, 20 and 40 mg/kg) the elimination half-life was approximately 14 min, the AUC(0-infinity) increased in a dose disproportional manner from 112.13 mg/L.min for 10 mg/kg to 758.19 mg/L.min for 40 mg/kg, indicating a non linear pharmacokinetic profile. After i.g. dosing at 100 mg/kg, plasma levels of wogonin peaked at 28 min with a C-max value of 300 ng/mL and a very low oral bioavailability (1.10%). Following i.v. single dose (20 mg/kg), wogonin was detected in all examined tissues (including testis) with the highest levels in kidney and liver. Approximately 21% of the administered dose was excreted as unchanged drug (mainly via non-biliairy fecal route (16.33%). Equilibrium dialysis was used to evaluate plasma protein binding of wogonin at three concentrations (0.1, 0.5 and 2 mu g/mL). Results indicated a very high protein binding degree (over 90%), reducing substantially the free fraction of the compound.